SOLV vs BSX vs DXCM Stock Comparison

Solventum, Boston Scientific and Dexcom Prices as of Nov 13, 2026 Peers: Industry group
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.27B
P/E
97.9x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
2 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$64.00B
P/E
18.3x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
3 wins
DXCM Dexcom Inc
$83.33 -0.2% 1M +39.5% 1Y
Market cap
$30.87B
P/E
31.2x
Revenue (TTM)
$5.10B
Div. yield
–
Medical Devices Healthcare
6 wins

Head to Head

11 decided of 12

Dexcom leads on 6 of the 12 questions below (Dexcom 6, Boston Scientific 3, Solventum 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSOLVBSXDXCMLeader
Larger companyMarket capitalisation $15.27B $64.00B $30.87B BSX
Cheaper on earningsLower P/E, profitable companies only 97.9x 18.3x 31.2x BSX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.8x 14.5x 29.1x SOLV
Faster revenue growthRevenue growth, trailing twelve months -2.8% +8.9% +13.0% DXCM
More profitableNet margin, trailing twelve months 1.9% 16.6% 19.4% DXCM
Better return on capitalReturn on invested capital 4.2% 9.9% 32.4% DXCM
Less leveragedLower net debt / EBITDA 4.7x 2.1x -0.9x DXCM
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +18.4% -57.8% +39.5% DXCM
Better 5-year returnAnnualised price return, 5 years — +1.1%/yr -12.4%/yr BSX
Less volatileAnnualised volatility, 1 year 30.1% 41.5% 37.9% SOLV
Higher overall scoreMean of the five percentile scores vs peers 51/100 68/100 80/100 DXCM

Percentile Scorecard

SOLVBSXDXCM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSOLVBSXDXCM
Valuation 70 #74 of 243 87 #33 of 243 67 #82 of 243
Growth 3 #221 of 228 68 #73 of 228 83 #40 of 228
Profitability 71 #66 of 222 91 #20 of 222 100 #1 of 222
Financial Health 15 #210 of 248 43 #142 of 248 59 #103 of 248
Shareholder Returns 94 #10 of 158 48 #82 of 158 91 #15 of 158
Overall 51 68 80
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics
  • DXCM ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSOLVBSXDXCMSPY
1 month +2.0%+3.1%-0.2% -2.0%
3 months +0.5%-14.5%-7.2% -2.8%
6 months +19.9%-15.8%+35.2% +2.0%
Year to date +12.4%-53.5%+25.6% +10.6%
1 year +18.4%-57.8%+39.5% +12.2%
3 years —-17.9%-17.8% +68.1%
3 years, per year —-6.4%-6.3% +18.9%
5 years —+5.4%-48.4% +61.4%
5 years, per year —+1.1%-12.4% +10.1%
10 years —+106.2%+411.2% +248.5%
10 years, per year —+7.5%+17.7% +13.3%

Risk

MeasureSOLVBSXDXCMSPY
Volatility, 1Y 30.1%41.5%37.9% 13.6%
Downside volatility, 1Y 29.3%47.7%34.3% 13.9%
Beta vs S&P 500, 1Y 0.610.260.72 1.00
Return / volatility, 1Y 0.61-1.391.04 0.90
Max drawdown, 5Y -40.0%-61.6%-66.3% -25.4%
From 52-week high -3.7%-57.8%-9.8% -3.2%
52-week high $92.45$104.98$92.34 $779.14
52-week low $62.49$41.57$57.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSOLVBSXDXCM
P/E now vs peer median 97.5xmedian 26.5x 18.3xmedian 26.5x 31.5xmedian 26.5x
P/S now vs peer median 1.9xmedian 2.7x 3.1xmedian 2.7x 6.1xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 14.1xmedian 18.4x 19.7xmedian 18.4x
P/FCF now vs peer median 156.0xmedian 25.4x 19.3xmedian 25.4x 28.3xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 2.5xmedian 2.5x 12.3xmedian 2.5x
PEG now vs peer median —median 0.98 0.42median 0.98 0.73median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSOLVBSXDXCM
Revenue $8.16B $21.07B $5.10B
Gross profit $4.47B $14.57B $3.24B
Operating income $454.00M $3.93B $1.22B
Net income $156.00M $3.49B $991.00M
Free cash flow – $3.33B $1.10B
R&D $723.00M $2.16B $608.10M
EPS (diluted) $0.91 $2.41 $2.58
Cash & equivalents $451.00M $609.00M $961.40M
Total debt $5.07B $11.95B $389.80M
Shares (diluted) 170.80M 1.45B 383.50M
Enterprise value $12.97B $59.43B $22.69B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSOLVBSXDXCM
P/E 97.5x 18.3x 31.5x
P/FCF 156.0x 19.3x 28.3x
P/Operating cash flow 48.8x 15.2x 22.0x
P/S 1.9x 3.1x 6.1x
P/B 3.1x 2.5x 12.3x
P/Tangible book 6.1x 3.4x 12.7x
EV/EBITDA 20.3x 14.1x 19.7x
EV/EBIT 43.5x 19.2x 24.2x
EV/Revenue 2.4x 3.6x 5.8x
EV/FCF – 22.7x 27.0x
EV/Operating cash flow 63.7x 17.9x 21.0x
PEG (3Y EPS CAGR) – 0.42 0.73

Growth

14 metrics
MetricSOLVBSXDXCM
Revenue growth (1Y) -2.8% 8.9% 13.0%
Revenue CAGR (3Y) – 15.3% 14.5%
Gross profit growth (1Y) -1.6% 9.8% 21.5%
Gross profit CAGR (3Y) – 15.1% 14.2%
Operating income growth (1Y) -79.3% 13.5% 57.4%
Operating income CAGR (3Y) – 22.1% 34.2%
Net income growth (1Y) -89.8% 25.5% 37.5%
Net income CAGR (3Y) – 41.7% 38.0%
EPS growth (1Y) -89.5% 29.2% 46.1%
EPS CAGR (3Y) – 44.0% 43.0%
Operating cash flow growth (1Y) -37.1% -8.5% -2.3%
Operating cash flow CAGR (3Y) – 21.6% 23.7%
Free cash flow growth (1Y) – -12.9% 3.4%
Free cash flow CAGR (3Y) – 25.2% 30.0%

Profitability

14 metrics
MetricSOLVBSXDXCM
Gross margin 54.8% 69.1% 63.4%
EBITDA margin 11.9% 25.5% 29.5%
Operating margin 5.6% 18.7% 24.0%
Pretax margin 2.1% 17.3% 24.7%
Net margin 1.9% 16.6% 19.4%
FCF margin – 15.8% 21.5%
Operating cash flow margin 3.8% 20.1% 27.7%
Return on equity 3.3% 13.7% 38.4%
Return on assets 1.1% 7.7% 15.6%
Return on invested capital 4.2% 9.9% 32.4%
Return on capital employed 4.3% 10.0% 29.9%
Asset turnover 0.6x 0.5x 0.8x
Cash conversion (OCF / net income) 2.0x 1.2x 1.4x
Stock comp / revenue 2.1% 1.5% 3.0%

Financial Health

11 metrics
MetricSOLVBSXDXCM
Debt / assets 35.8% 26.3% 6.2%
Debt / equity 1.1x 0.5x 0.2x
Net debt / EBITDA 4.7x 2.1x -0.9x
Debt / FCF – 3.6x 0.4x
Liabilities / assets 66.1% 43.1% 59.4%
Equity / assets 33.9% 56.9% 40.6%
Interest coverage – 10.5x –
Current ratio 1.0x 1.4x 1.7x
Quick ratio 0.5x 0.6x 1.3x
Cash ratio 0.1x 0.1x 0.8x
Altman Z-score 1.85 3.03 7.53

Shareholder Returns

7 metrics
MetricSOLVBSXDXCM
Dividend yield – – –
Net buyback yield 2.7% -0.3% 2.2%
Shareholder yield 2.7% -0.3% 2.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSOLVBSXDXCM
Forward P/E 12.8xFY2026 14.5xFY2026 29.1xFY2026
EPS, next fiscal year $6.93FY2026 $3.06FY2026 $2.86FY2026
EPS growth, next FY +13.4%FY2026 0.0%FY2026 +36.8%FY2026
EPS growth, the year after +15.3% +8.2% +4.2%
Revenue, next fiscal year $7.71BFY2026 $20.48BFY2026 $5.08BFY2026
Revenue growth, next FY -7.3%FY2026 +2.1%FY2026 +9.0%FY2026
Revenue growth, the year after +5.8% -4.0% +16.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSOLVBSXDXCM
Held by institutions 73.9% 90.5% 100.0%
Institutions holding 882 1,484 977
Change in shares held, QoQ -0.9% -0.7% +6.3%
Institutions buying 370 738 521
Institutions selling 286 612 345
Buyers to sellers 1.29 1.21 1.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SOLVBSXDXCM
SOLV 1.00 0.23 0.27
BSX 0.23 1.00 0.31
DXCM 0.27 0.31 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SOLV, BSX and DXCM?

Boston Scientific (BSX) is the largest by market capitalisation: Solventum (SOLV) $15.27B, Boston Scientific (BSX) $64.00B, Dexcom (DXCM) $30.87B.

Which stock is cheaper, SOLV, BSX and DXCM?

Boston Scientific (BSX) trades on the lowest price-to-earnings ratio (Solventum (SOLV) 97.9x, Boston Scientific (BSX) 18.3x, Dexcom (DXCM) 31.2x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Solventum (SOLV) 12.8x, Boston Scientific (BSX) 14.5x, Dexcom (DXCM) 29.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Dexcom (DXCM) grew revenue fastest over the trailing twelve months: Solventum (SOLV) -2.8%, Boston Scientific (BSX) +8.9%, Dexcom (DXCM) +13.0%.

Which company is more profitable?

Dexcom (DXCM) has the highest net margin (Solventum (SOLV) 1.9%, Boston Scientific (BSX) 16.6%, Dexcom (DXCM) 19.4%). On return on invested capital, Dexcom (DXCM) leads (Solventum (SOLV) 4.2%, Boston Scientific (BSX) 9.9%, Dexcom (DXCM) 32.4%).

Which stock has performed better?

Over the past year Dexcom (DXCM) returned the most: Solventum (SOLV) +18.4%, Boston Scientific (BSX) -57.8%, Dexcom (DXCM) +39.5%. Over five years, Boston Scientific (BSX) compounded fastest (Boston Scientific (BSX) +1.1%/yr, Dexcom (DXCM) -12.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Solventum (SOLV) has been the steadiest (Solventum (SOLV) 30.1%, Boston Scientific (BSX) 41.5%, Dexcom (DXCM) 37.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, SOLV, BSX and DXCM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Dexcom (DXCM) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.